661 abstracts found.



Results filter

Defining DDR deficiency and replication stress in pancreatic cancer

Year:

Session type:

Stephan Dreyer1,Viola Paulus-Hock2,Eirini-Maria Lampraki1,Rosanna Upstill-Goddard1,Giusseppina Caligiuri1,Holly Brunton3,Bryan Serrels1,Richard Cunningham1,Nigel Jamieson1,Colin McKay1,Peter Bailey1,Susie Cooke1,Andrew Biankin1,David Chang1
1University of Glasgow,2Beatson Institute of Cancer Research,3University of GLasgow

Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis

Year:

Session type:

Madelon Paauwe1,Mark Schoonderwoerd2,Roxan Helderman2,Tom Harryvan2,Arwin Groenewoud3,Gabi van Pelt2,Rosalie Bor2,Danielle Hemmer2,Henri Versteeg2,Ewa Snaar-Jagalska3,Charles Theuer4,James Hardwick2,Cornelis Sier2,Peter ten Dijke2,Lukas Hawinkels2
1Beatson Institute for Cancer Research,2Leiden University Medical Center,3Institute of Biology, Leiden University,4Tracon Pharmaceuticals

PERSEPHONE: A randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC)

Year:

Session type:

Helena Earl1,Louise Hiller2,Anne-Laure Vallier1,Shrushma Loi3,Donna Howe2,Helen Higgins2,Karen McAdam1,Luke Hughes-Davies1,Adrian Harnett4,Mei-Lin Ah-See5,Richard Simcock6,Daniel Rea7,Janine Mansi8,Jean Abraham1,Carlos Caldas1,Claire Hulme9,David Miles5,Andrew Wardley10,David Cameron11,Janet Dunn2
1Cambridge University Hospitals,2University of Warwick,3University of Birmingham,4Norfolk and Norwich University Hospital,5Mount Vernon Cancer Centre,6Royal Sussex County Hospital,7Sandwell and West Birmingham Hospitals NHS Trust,8Guy's Hospital,9University of Leeds,10Christie Research Facility,11University of Edinburgh

Improving the intra-operative diagnosis of high-grade glioma using a fluorescence biomarker – result of the UK NCRI GALA-BIDD study

Year:

Session type:

Colin Watts1,Keyoumars Ashkan2,Michael Jenkinson3,Kathreena Kurian4,Wendi Qian5,Stephen Price5,Tomasz Matys6,Gail Doughton5,Andrea Machin5,Josephine Jung2,Ibrahim Jalloh3,Chloe Harman5,Katrina Gatley5,Gemma Young5,Richard Hardy5,Alimu Dayimu7

1University of Birmingham,2Kings College Hospital,3University of Liverpool,4Southmead Hospital,5Cambridge University Hospitals NHS Foundation Trust,6University of Cambridge,7Shandong University


The impact of biomarker status on predicting outcome in patients following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases

Year:

Session type:

Dilraj Bhullar1,Sarah O'Dwyer1,Malcolm Wilson1,Chelliah Selvasekar2,Andrew Renehan1,Paul Fulford2,Omer Aziz1
1The Christie NHS Foundation Trust & The University of Manchester,2The Christie NHS Foundation Trust

Aspirin use after radical cancer therapy – feasibility and toxicity data from the Add-Aspirin trial

Year:

Session type:

Nalinie Joharatnam1,Fay Cafferty1,Alistair Ring2,Howard Kynaston3,Richard Wilson4,Duncan Gilbert5,David Cameron6,Farhat Din6,Richard Hubner7,Anne Thomas8,Daniel Swinson9,Janusz Jankowski10,Sam Rowley11,Martin Scott-Brown12,Chris Price13,Alex Walther14,David Eaton15,Nicola Ainsworth16,Rachel Kerr17,Luke Hughes-Davies18,Max Parmar1,Conjeeveram Pramesh19,Sudeep Gupta19,Ruth Langley1
1MRC Clinical Trials Unit at UCL,2The Royal Marsden NHS Foundation Trust,3Cardiff and Vale University Health Board,4Queen's University Belfast,5Brighton and Sussex University Hospitals NHS Trust,6The University of Edinburgh,7The Christie NHS Foundation Trust,8University Hospitals of Leicester,9Leeds Teaching Hospitals NHS Trust,10University of Central Lancashire,11MRC CTU at UCL,12University Hospitals of Coventry and Warwickshire NHS Trust,13Worcestershire Acute Hospitals NHT Trust,14University Hospitals Bristol NHS Foundation Trust,15University Hospitals of Morecambe Bay NHS Foundation Trust,16The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust,17Oxford University Hospitals NHS Trust,18Cambridge University Hospitals NHS Foundation Trust,19Tata Memorial Centre

Progression free survival as a surrogate endpoint for overall survival in first-line therapy of advanced ovarian cancer: A Gynecologic Cancer InterGroup (GCIG) individual patient-level meta-analysis

Year:

Session type:

Rosalind Glasspool1,Liz-Anne Lewsley2,Gennaro Daniele3,Adrian David Cook4,Nozomu Yanaihara5,Anna Tinker6,Gunnar Kristensen7,Petronella Ottevanger8,Gerasimos Aravantinos9,Ingrid A. Boere10,Robert Fruscio11,Anna K.L. Reyners12,Eric Pujade-Lauraine13,Andrea Harkin2,Sandro Pignata14,Tatsuo Kagimura15,Stephen Welch16,Eleni, Karamouza17,Stan Kaye18,Timothy Perren19,Susana N Banerjee20,Xavier Paoletti21
1Beatson West of Scotland Cancer Centre,2Cancer Research UK Clinical Trials Unit, Institute of Cancer Research, University of Glasgow, Glasgow,,3Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”- IRCCS, Naples,4MRC Clinical Trials Unit at UCL, London,,5The Jikei University School of Medicine, Tokyo,6British Columbia Cancer Agency, Vancouver, BC,,7Norwegian Radium Hospital, Oslo,8Department of Medical Oncology, Radboud University Medical Center, Nijmegen,9Hellenic Cooperative Oncology Group (HeCOG), Athens,10Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam,11University of Milan & Bicocca San Gerardo Hospital, Monza,,12University Medical Center, University of Groningen, Groningen,,13Universite Paris-Descartes, AP-HP, Paris,,14National Cancer Institute of Naples, Naples,,15Foundation for Biomedical Research and Innovation, Translational Research Informatics Center, Kobe,,16London Regional Cancer Program, London, ON,,17Ligue Nationale Contre le Cancer Meta-Analysis Platform, Department of Biostatistics and Epidemiology, Gustave-Roussy Cancer Campus, Villejuif,,18The Institute of Cancer Research and The Royal Marsden Hospital, Sutton,19Leeds Teaching Hospitals NHS Trust, Leeds,20The Royal Marsden NHS Foundation Trust, London,,21Gustave Roussy Institute, Villejuif

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects

Year:

Session type:

A Murray Brunt1,Joanne Haviland2,Mark Sydenham2,Abdulla Alhasso3,David Bloomfield4,Charlie Chan5,Mark Churn6,Susan Cleator7,Charlotte Coles8,Marie Emson2,Andrew Goodman9,Clare Griffin2,Adrian Harnett10,Penny Hopwood2,Anna Kirby11,Cliona Kirwan12,Carolyn Morris13,Elinor Sawyer14,Navita Somaiah2,Isabel Syndikus15,Maggie Wilcox13,Zotova Rada16,Duncan Wheatley17,Judith Bliss2,John Yarnold2
1University Hospitals of North Midlands NHS Trust and Keele University,2The Institute of Cancer Research,3The Beatson West of Scotland Cancer Centre,4Brighton and Sussex University Hospitals NHS Trust,5Nuffield Health Cheltenham Hospital,6Worcestershire Acute Hospitals NHS Trust,7Imperial College Healthcare NHS Trust,8Cambridge University Hospitals NHS Foundation Trust,9Royal Devon and Exeter NHS Foundation Trust,10Norfolk and Norwich University Hospitals NHS Foundation Trust,11The Royal Marsden Hospital NHS Foundation Trust,12Manchester University NHS Foundation Trust,13Independent Cancer Patients' Voice,14Guy's and St Thomas' NHS Foundation Trust,15Wirral University Teaching Hospital NHS Foundation Trust,16RTTQA Mount Vernon Hospital,17Royal Cornwall Hospitals NHS Trust

Precision therapy in the p53 pathway

Year:

Session type:

Chit Fang Cheok1,Luis Coronel2,Ramesh Kumar3,Bhagi Somalanka3,Raju Anandh1,Obed Aning4,Ping Yin Hor5,An Omer6,Yingswan Ho7,Chen Shuwen7,Shi Ya Mak7,Henry Yang8,Mani LAKSHMANAN4,Hideki Itoh9,Soo Yong Tan10,Timothy Lim11,Adele Wong11,Sung Hock Chew11,The Hung Huynh12,Boon Cher Goh13,Vinay Tergoankar4,Chin Yan Lim9
1Institute of Molecular and Cell Biology (IMCB), A*STAR,2p53Laboratory, A*STAR,3IFOM-p53Lab JRL,4Institute of Molecular and Cell Biology (IMCB),5IFOM-p53Lab, A*STAR,6Cancer Science Institut, NUS,7Bioprocessing Technology Institute, A*STAR,8Cancer Science Institute, NUS,9Institute of Medical Biology, A*STAR,10Department of Pathology, NUS,11KK Women’s and Children’s Hospital,12National Cancer Center Singapore,13National University Cancer Institute

HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): a randomised controlled trial of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible.

Year:

Session type:

Richard Shaw1,HOPON Trial Co-investigators and Trial Management Group N/a2
1University of Liverpool,2N/A

The Lung Screen Uptake Trial (LSUT): Applying behavioural science to optimise informed participation among high-risk and socioeconomically deprived groups

Year:

Session type:

Samantha Quaife1,Mamta Ruparel1,Jennifer Dickson1,Rebecca Beeken2,Andy McEwen3,David Baldwin4,Angshu Bhowmik5,Neal Navani6,Stephen Duffy7,Jo Waller1,Samuel Janes1
1University College London,2University of Leeds,3National Centre for Smoking Cessation and Training,4Nottingham University Hospitals,5Homerton University Hospital,6University College London Hospital,7Queen Mary University of London